Published in Eur Heart J on September 15, 2015
Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. Circulation (2016) 1.14
Advances in the pharmacotherapy of chronic heart failure with preserved ejection fraction: an ideal opportunity for precision medicine. Expert Opin Pharmacother (2017) 0.78
Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions. Curr Heart Fail Rep (2017) 0.78
Defining HFpEF: where do we draw the line? Eur Heart J (2015) 0.75
Echocardiography for Evaluation of Oncology Therapy-Related Cardiotoxicity. Acta Cardiol Sin (2016) 0.75
Current Drug Therapy in Chronic Heart Failure: the New Guidelines of the European Society of Cardiology (ESC). Korean Circ J (2017) 0.75
Targeting Obesity and Diabetes to Treat Heart Failure with Preserved Ejection Fraction. Front Endocrinol (Lausanne) (2017) 0.75
Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome. Clin Res Cardiol (2016) 0.75
Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr (2005) 46.32
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med (1999) 29.32
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med (2003) 13.25
Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med (2008) 9.62
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48
The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J (2011) 2.97
Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation (2005) 2.78
Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation (2014) 1.77
Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circ Heart Fail (2013) 1.40
The middle child in heart failure: heart failure with mid-range ejection fraction (40-50%). Eur J Heart Fail (2014) 1.10
Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail (2014) 1.07
The treatment of heart failure with preserved ejection fraction ("diastolic heart failure"). Heart Fail Rev (2006) 0.96
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48
Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circ Heart Fail (2013) 1.40
Transatlantic similarities and differences in major natural history endpoints of heart failure after acute myocardial infarction: a propensity-matched study of the EPHESUS trial. Int J Cardiol (2009) 0.89
Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. Eur J Heart Fail (2011) 0.82
Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial. Circ Heart Fail (2016) 0.78
Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction. Eur Heart J (2015) 0.77
Sudden cardiac death in heart failure with preserved ejection fraction: a target for therapy? Heart Fail Rev (2016) 0.75
Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment. Eur J Heart Fail (2016) 0.75
Influence of ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction. Eur J Heart Fail (2017) 0.75
Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial. Eur J Heart Fail (2017) 0.75
Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial. Arch Cardiovasc Dis (2014) 0.75